Pulmonary Arterial Hypertension Pipeline Insight Research Report | 55+ Companies and 55+ Pipeline Drugs | DelveInsight

DelveInsight's, "Pulmonary Arterial Hypertension Pipeline Insight, 2022," report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in the Pulmonary Arterial Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Around 55+ key companies are developing therapies for Pulmonary Arterial Hypertension, among which the drug Liquidia Technologies is in the advanced stage (Pre-Registration).

Key takeaways from the Pulmonary Arterial Hypertension Pipeline Insight Report
• DelveInsight's Pulmonary Arterial Hypertension pipeline report depicts a robust space with 55+ active players working to develop 55+ pipeline therapies for various indications.
• The leading Pulmonary Arterial Hypertension Companies are working such as Galectin Therapeutics, Pfizer, Aerami Therapeutics, PhaseBio Pharmaceuticals, Bial, Gossamer Bio, Arena Pharmaceuticals, United Therapeutics, Acceleron Pharma, Bristol Myers Squibb, and others are developing potential drug candidates to improve the Pulmonary Arterial Hypertension treatment scenario.
• Promising Pulmonary Arterial Hypertension Pipeline therapies such as Sotatercept, LIQ861, Model 10642 Implantable Intravascular Catheter, Epoprostenol, Treprostinil, Non-Treprostinil PAH Medications, TPN171H, Macitentan, Selexipag, macitentan (ACT-064992), and others.
• The Pulmonary Arterial Hypertension Companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Arterial Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve Pulmonary Arterial Hypertension.
Recent Developmental Activities in the Pulmonary Arterial Hypertension Pipeline
• The United States Food and Drug Administration (FDA) has granted Orphan Drug designation and Breakthrough Therapy designation to sotatercept for the treatment of PAH.
• The European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of PAH. In December 2020, Acceleron Pharma announced that the European Commission (EC) had granted orphan designation to sotatercept to treat patients with pulmonary arterial hypertension (PAH). Sotatercept is part of a licensing agreement with Bristol Myers Squibb.
• The orphan drug, Flolan (epoprostenol sodium for injection or prostacyclin) has been approved as a standard long-term treatment of individuals with severe PAH.
• The FDA has granted the orphan drug treprostinil (Remodulin) in subcutaneous and intravenous forms and Tyvaso, an inhaled form of treprostinil, and oral form (Orenitram) for the treatment of PAH.
• The FDA approved iloprost (Ventavis) for the PAH treatment. The treatment is inhaled via the mouth with the assistance of a special nebulizer, dilating the arteries and inhibiting the formation of blood clots.
• Revatio (sildenafil), a phosphodiesterase type 5 (PDE5) inhibitor, also treats PAH.
• In August 2021, United Therapeutics Corporation announced it would present data from a clinical trial studying Tyvaso DPI (treprostinil) in patients with pulmonary arterial hypertension (PAH) at the European Respiratory Society (ERS) International Congress 2021, which will be held virtually from September 5-8, 2021.
• In July 2021, PulmoSIM Therapeutics (PulmoSIM) announced that it has entered into a strategic partnership with the investigators from National Jewish Health and Brown University for the clinical development of PT001. This drug targets multiple responsible pathways in PAH to provide curative treatment.
• In June 2021, PulmoSIM Therapeutics (PulmoSIM) announced that the U.S. Food and Drug Administration (FDA) had granted orphan drug designation for asset PT001 for the treatment of Pulmonary Arterial Hypertension (PAH).
• In January 2021, PhaseBio Pharmaceuticals, Inc. announced the presentation of data from a Phase Ib/IIa pilot study highlighting three patients who received pemziviptadil (PB1046), the company's first-in-class, sustained-release vasoactive intestinal peptide (VIP) analog for the treatment of pulmonary arterial hypertension (PAH).

Request a sample and discover the recent advances in Pulmonary Arterial Hypertension Pipeline Outlook Report @ https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pulmonary Arterial Hypertension Overview

Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening blood vessel disorder. PAH is characterized by a thickening of the pulmonary vasculature, leading to restricted blood flow and elevated blood pressure within the pulmonary vessels. The tests that are commonly performed to diagnose PAH and rule out other diseases are echocardiography, blood tests, pulmonary function tests, X-rays of the chest, lung blood flow scans, electrocardiography (ECG), and the "6-minute walk test", which measures how far an individual can walk in that time period. Treatment for PAH includes prostaglandins, endothelin receptor antagonists, phosphodiesterase Type 5 inhibitors. Other treatments such as anticoagulants, diuretics, and oxygen may be used to treat PAH as supportive therapies.

Pulmonary Arterial Hypertension Emerging Drugs

Sotatercept: Acceleron Pharma

Sotatercept is a first-in-class therapeutic fusion protein comprised of the extracellular domain of human activin receptor type IIA, fused to the Fc domain of human immunoglobulin G1 (IgG1). It provides balance of the growth-promoting activin growth differentiation factor pathway, and the growth-inhibiting BMP pathway by serving as a ligand trap for the TGF-β superfamily. The United States Food and Drug Administration (FDA) has granted Orphan Drug designation and Breakthrough Therapy designation to sotatercept for the treatment of PAH; the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of PAH. Sotatercept is in Phase III clinical trial for the treatment of PAH.

LIQ861: Liquidia Technologies

LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed using the Company's novel PRINT technology and engineered with the goal of enhancing deep-lung delivery of treprostinil in PAH patients by means of a convenient, palm-sized dry powder inhaler. Liquidia resubmits New Drug Application for LIQ861 under the 505(b)(2) regulatory pathway for the treatment of pulmonary arterial hypertension (PAH).

Pulmonary Arterial Hypertension Pipeline Therapeutics Assessment

There are approx. 55+ key companies which are developing the therapies for Pulmonary Arterial Hypertension. The companies which have their Pulmonary Arterial Hypertension drug candidates in the most advanced stage, i.e. Preregistration include, Liquidia Technologies.

Find out more about Pulmonary Arterial Hypertension Clinical Trials Analysis @ https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pulmonary Arterial Hypertension Pipeline Report Assessment
• Pulmonary Arterial Hypertension Pipeline Product Profiles
• Pulmonary Arterial Hypertension Therapeutic Assessment
• Pulmonary Arterial Hypertension Pipeline Assessment
• Inactive drugs assessment
• Pulmonary Arterial Hypertension Unmet Needs

Scope of the Pulmonary Arterial Hypertension Pipeline Report
• Coverage- Global
• Pulmonary Arterial Hypertension Companies- Galectin Therapeutics, Pfizer, Aerami Therapeutics, PhaseBio Pharmaceuticals, Bial, Gossamer Bio, Arena Pharmaceuticals, United Therapeutics, Acceleron Pharma, Bristol Myers Squibb, and others.
• Pulmonary Arterial Hypertension Pipeline therapies- Sotatercept, LIQ861, Model 10642 Implantable Intravascular Catheter, Epoprostenol, Treprostinil, Non-Treprostinil PAH Medications, TPN171H, Macitentan, Selexipag, macitentan (ACT-064992), and others

Table of Content
1. Introduction
2. Executive Summary
3. Pulmonary Arterial Hypertension: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Pulmonary Arterial Hypertension - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Sotatercept: Acceleron Pharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. GB-002: Gossamer Bio
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Apabetalone: Resverlogix
15. Drug profiles in the detailed report…..
16. Preclinical/Discovery Stage Products
17. R107: Radikal Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Pulmonary Arterial Hypertension Key Companies
21. Pulmonary Arterial Hypertension Key Products
22. Pulmonary Arterial Hypertension- Unmet Needs
23. Pulmonary Arterial Hypertension- Market Drivers and Barriers
24. Pulmonary Arterial Hypertension- Future Perspectives and Conclusion
25. Pulmonary Arterial Hypertension Analyst Views
26. Appendix

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Pulmonary Arterial Hypertension drugs?
• How many Pulmonary Arterial Hypertension drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pulmonary Arterial Hypertension?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Arterial Hypertension therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pulmonary Arterial Hypertension and their status?
• What are the key designations that have been granted to the emerging drugs?

For further information on the Pulmonary Arterial Hypertension Pipeline therapeutics, reach out @ https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.